Premium
Toxicity and preliminary results with a new eight‐drug regimen (CEOP‐IMVP‐DEXA) in the treatment of aggressive lymphomas
Author(s) -
Fridrik M. A.,
Hausmaninger H.,
Michlmayr G.,
Haidinger R.,
Seewann H. L.,
Lehnert M.
Publication year - 1991
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2900090406
Subject(s) - medicine , complete remission , surgery , regimen , lymphoma , gastroenterology , chemotherapy
A combination of two non‐cross‐resistant regimens, CEOP and IMVP‐Dexa given every 4 weeks, three to six times according to response was tested in patients with untreated histological proven high and intermediate grade non‐Hodgkin's lymphoma. To date eight Austrian centres entered 37 patients in this multicentre trial. Data are available from 33 patients, three were excluded, two because of pretreatment, one because of wrong histology. Twenty‐five patients are evaluable for response, 21 had a complete and three a partial remission, two of them entered a complete remission after radiotherapy to residual disease, resulting in a complete remission rate of 92 per cent. Only one patient progressed during therapy. Until now three patients relapsed after achieving a remission. Observation time is 0±4–23±8 months, median 8±8 months. Toxicity was primarily hematologic with 53·3 per cent of patients having granulocyte nadirs below 0·5 × 10 9 /L and 3·3 per cent below 0·1 × 10 9 /L. Although 60 per cent of patients had infections, there was only one life‐threatening infection in an AIDS patient. CEOP‐IMVP‐Dexa can be safely given even in smaller hematologic centres and is able to achieve a high rate of complete responses in patients with high and intermediate grade malignant non‐Hodgkin's lymphomas.